STOCKS TELEGRAPH

Category: Mid Day Movers

  • Pre-Hour Boost For Rocket Lab (RKLB) As It Joins U.S. Space Force Initiative

    Pre-Hour Boost For Rocket Lab (RKLB) As It Joins U.S. Space Force Initiative

    Rocket Lab USA, Inc. (NASDAQ: RKLB) shares are soaring after the company was announced to be accepted into a prominent defense program. The most recent pre-market check showed that RKLB stock was up 7.65%, trading at $19.83. The company’s recent inclusion in the National Security Space Launch (NSSL) Phase 3 Lane 1 program of the U.S. Space Force is credited with this momentum.

    Major Contract Award and Development of Neutron Rocket

    As part of the NSSL program, the U.S. Space Force has selected Rocket Lab to compete for critical national security missions. The deal, which has a five-year term and a potential value of $5.6 billion, will end in June 2029. It is designed to deliver high-assurance space launch services for the Department of Defense’s most important missions.

    The endeavor will be launched from Rocket Lab’s Neutron rocket, a 13-ton, medium-lift vehicle constructed from reusable carbon composites. The development of neutrons is accelerating to fulfill the needs of satellite constellation deployments and national security.

    Neutron’s Market Readiness and Rocket Lab’s Reputation

    Neutron is capable of deploying payloads up to 13,000 kilograms, making it a powerful addition to Rocket Lab’s growing portfolio. With 63 successful Electron launches, the company has established itself as a reliable provider, one of the few U.S. companies to achieve multiple payload launches in 2025. Neutron’s anticipated debut later this year will set the stage for RKLB’s future engagements with the NSSL program, pending a successful first flight.

    Strategic Role in U.S. National Security

    As one of just five companies selected for the NSSL Phase 3 program, Rocket Lab’s inclusion underscores its eligibility to compete for further national security missions. The program, which plans to award at least 30 missions through 2029, could extend into 2034.

    To initiate its participation, RKLB has already secured a $5 million task order to conduct a capabilities assessment, demonstrating its commitment to mission assurance and ensuring reliable access to space for the nation’s most critical defense objectives.

  • Pre-Hour Trading Sees Braze (BRZE) Stock Jump On Strategic Moves

    Pre-Hour Trading Sees Braze (BRZE) Stock Jump On Strategic Moves

    Shares of Braze, Inc. (NASDAQ: BRZE) had a significant boost in pre-market trading, climbing 11.69% to $40.99. Following the release of the fiscal year financial statistics and the announcement of a strategic acquisition, investor confidence in BRZE’s development trajectory has grown.

    Consistent Financial Growth and Profitability

    When Braze revealed its remarkable financial results for the fiscal year that ended on January 31, 2025, it achieved a major milestone in its evolution as a leading platform for consumer contact. At $593.4 million, the company’s annual revenue grew by 26%.

    Furthermore, by sustaining non-GAAP net income profitability for three straight quarters, Braze demonstrated excellent operating leverage. The fourth quarter’s revenue of $160.4 million was a 22.5% increase over the prior year. The primary forces behind this growth were subscription renewals, upselling initiatives, and customer acquisition.

    BRZE’s dollar-based net retention rate was 111% for all clients and 114% for those with annual recurring revenue (ARR) over $500,000, a little drop from the previous year’s figures of 117% and 120%, respectively.

    Furthermore, Braze’s customer base increased dramatically, from 2,044 in January 2024 to 2,296 in January 2025. Notably, within the same time period, there were 247 customers who generated an ARR of $500,000 or more, up from 202 in the previous period.

    Purchasing Strategically to Boost AI Capabilities

    The business made a big announcement when it revealed its intention to buy OfferFit, an artificial intelligence (AI) decisioning business that specializes in reinforcement learning for individualized cross-channel client interaction. The purchase, which is estimated to be worth $325 million, is contingent to standard closing requirements.

    Improving Customer Engagement Driven by AI

    Braze has been at the forefront of technical developments in consumer involvement since its founding more than ten years ago. It is anticipated that the delivery of real-time, customized customer interactions would be improved by the merging of BRZE’s current capabilities with OfferFit’s AI-powered solutions.

    The business wants to reimagine the future of AI-powered customer interaction by fusing Braze’s AI-driven orchestration and messaging solutions with OfferFit’s reinforcement learning technology.

  • Argan (AGX) Gains In Pre-Market Session After Strong Financials

    Argan (AGX) Gains In Pre-Market Session After Strong Financials

    Following the announcement of its most recent financial results, Argan, Inc.’s (NYSE: AGX) shares saw a notable increase. AGX shares increased 12.82% to $130.00 during pre-market trading. This rising momentum was aided by the company’s fiscal 2025 full-year and fourth-quarter financials, which demonstrated outstanding execution across all business areas.

    Strong Growth in Services

    The power industry services area was a highlight of Argan’s quarterly performance, with sales rising by 65% to $196.9 million. This segment’s gross margin was a remarkable 21.3%.

    With a gross margin of 20.5%, the company’s consolidated fourth-quarter revenue increased 41% year over year to $232.5 million. EBITDA was $39.3 million, while net income hit a new high of $31.4 million, or $2.22 per diluted share.

    Growing Project Backlog

    As of January 31, 2025, Argan has $1.4 billion in unfinished projects. This amount includes complete notifications to go forward on important projects including a 300 MW biofuel power station in Ireland and a 700 MW combined-cycle natural gas plant in the United States.

    The business also signed a contract for a 1.2 GW ultra-efficient natural gas-fired power plant in Texas after the fiscal quarter ended. As fiscal 2026 gets underway, the business is still hopeful about new market prospects.

    Taking Advantage of Growing Energy Demands

    Argan , a provider of diverse energy solutions, has established a great reputation for effectively completing challenging projects. The pressing need for dependable energy solutions is highlighted by the growing demand for electrification, deteriorating power infrastructure, and a decade of underinvestment in natural gas facilities.

    Prospects for the Future

    Argan is positioned as a major participant in this changing environment because of its experience with both renewable energy and natural gas projects. Large-scale power projects usually take three to four years to complete, thus Argan anticipates a steady development trajectory.

    AGX is steadfast in its resolve to increase its influence on the development of the energy infrastructure of the future by utilizing its technological prowess, industry connections, and financial stability.

  • Portage Biotech (PRTG) Shares Skyrocket In Pre-Hour Trading

    Portage Biotech (PRTG) Shares Skyrocket In Pre-Hour Trading

    The stock value of Portage Biotech Inc. (NASDAQ: PRTG) skyrocketed following the release of promising preclinical results. PRTG stock was selling at $9.64 as of the most recent pre-market check, representing a startling 103.81% rise.

    Innovation in the Treatment of Mesothelioma

    Portage Biotech presented fresh preclinical results on PORT-7 (TT-4), a selective Adenosine A2B receptor inhibitor, at the 2025 European Lung Cancer Congress (ELCC), which took place in Paris from March 26 to 29. Dr. Luciano Mutti of Gruppo Italiano Mesotelioma e Oncologia Ambientale conducted the study, which showed encouraging anticancer activity.

    Results showed that PORT-7 significantly suppressed tumors when taken alone. More significantly, in a mouse mesothelioma model, it suppressed tumor development by over 90% when paired with an anti-PD1 antibody.

    Furthermore, immunohistochemical examination of treated tumors revealed a significant infiltration of immune effector cells that are CD3 and CD45 positive. These results demonstrate PORT-7’s potential in tackling immune resistance pathways, which is important given the aggressive nature of mesothelioma and the lack of viable treatment alternatives.

    Advancements in Strategic Clinical Practice

    PORT-7’s first-in-human clinical study is currently being prepared by Portage Biotech. At the same time, the business is developing PORT-6, a strong and specific A2A adenosine receptor inhibitor, in its dose escalation phase.

    As part of the ADPORT-601 study, plans are underway to co-administer PORT-6 and PORT-7, which would be the first time that patients would receive both highly specific A2A and A2B antagonists. By completely preventing adenosine-induced immunosuppression in the tumor microenvironment, this dual-inhibitor approach may improve the effectiveness of immunotherapy in solid tumors.

    PORT-6 Clinical Trials Resuming

    Following a brief halt due to financial limitations, Portage Biotech has reopened patient recruitment in the fourth and final cohort of its Phase 1b ADPORT-601 study for PORT-6. The continuance of the experiment demonstrates faith in the therapeutic potential and safety of PORT-6.

    In order to advance its immunotherapy pipeline, PRTG will evaluate the feasibility of expanding the research to include PORT-7 and combo arms when this phase is over. These recent advancements put Portage Biotech at the forefront of immuno-oncology innovation and reinforced its dedication to developing cutting-edge medicines for tumors that are difficult to cure.

  • Hertz Global (HTZ) Strengthens Operations With Tech-Driven Upgrade

    Hertz Global (HTZ) Strengthens Operations With Tech-Driven Upgrade

    After Getac’s cutting-edge technological solutions were incorporated into Hertz Global Holdings, Inc.’s (NASDAQ: HTZ) operations, its stock value increased by a substantial 22%, to $4.21 as of the last check today. HTZ’s customer service experience has significantly improved as a result of this advancement, particularly at airport sites.

    Enhanced Customer Support with Rugged Solutions

    At a few U.S. locations, Hertz Global has unveiled Getac’s rugged hardware and software solutions, most notably the UX10 rugged tablet. By doing away with human processes, this new technology seeks to expedite the airport pickup and drop-off process. As a consequence, agents are better equipped to serve more clients quickly during busy periods, reducing wait times and improving overall service quality.

    Features Designed to Increase Operational Efficiency

    The customized UX10 tablets feature several key components to meet Hertz Global’s specific needs. These include certificates guaranteeing the device’s resilience in harsh environments, a barcode scanner for instant access to client reservation data, and a camera to record vehicle damage. The devices are covered by a three-year warranty, which reduces the possibility of downtime and guarantees continuous servicing.

    Additionally, the integration of the Getac Device Monitoring System offers HTZ real-time visibility into device performance. This system tracks device usage, monitors those in need of repair, and helps assess the need for replacement equipment, offering time and cost savings.

    Seamless Integration with Hertz Global Platforms

    In addition to enhancing the rental experience, Getac’s technology works flawlessly with Hertz Global’s current setup. Effective inventory management and vehicle damage evaluations are now possible thanks to the rugged tablets’ syncing with HTZ’s digital Vehicle Information Reporting Systems (VIRS). Monitoring maintenance alerts, such recall warnings or oil change notifications, may help improve the operational process.

    A Technological Advancement to Gain a Competitive Advantage

    Hertz Global has greatly improved its operational efficiency and customer service skills by implementing Getac’s solutions. HTZ is better positioned to compete in the quick-paced rental vehicle industry because of its technology-driven strategy, which also increases customer happiness and employee efficiency.

  • Jiayin Group (JFIN) Stock Gains Momentum On Strong Fiscal Report

    Jiayin Group (JFIN) Stock Gains Momentum On Strong Fiscal Report

    Shares of Jiayin Group Inc. (NASDAQ: JFIN) surged 22.69% to $14.85 on the release of the company’s fourth-quarter and full-year financial results. The exceptional stock performance is a reflection of its sound financial standing and strategic approach in a difficult market climate.

    Outstanding Financial Results for Q4 and Fiscal Year 2024

    Jiayin recorded net sales of RMB5,801.0 million ($792.4 million) for the fiscal year that ended on December 31, 2024, which is a 6.1% increase from the previous year. The net income for the quarter was RMB275.5 million ($37.7 million), while the net revenue for the fourth quarter alone was RMB1,404.5 million ($192.4 million).

    With a full-year net income of RMB1,056.5 million ($144.7 million), JFIN demonstrated its sustained profitability and fortitude in the face of market difficulties.

    Growth Driven by Innovation and AI Integration

    Jiayin focused on innovation to continue growth in 2024, taking advantage of both possibilities and challenges. The widespread application of artificial intelligence (AI) throughout its operations was a crucial tactic. JFIN strengthened risk management procedures and increased efficiency by streamlining services and client groups.

    With this strategy, the business was able to keep adding value for stakeholders while increasing the amount of loans it facilitated by 14.4% annually to RMB100.8 billion.

    Returns to Shareholders and Prospects

    By announcing a cash dividend of $0.5 per American depositary share, or around $26.6 million, Jiayin further showed its dedication to its stockholders. For FY2023, this dividend amounts to 15% of its net profits after taxes. As market conditions improve, JFIN expects more dividend returns.

    Jiayin is also committed to expanding internationally and broadening its funding sources, while maintaining a focus on the application of AI and responsible risk management. JFIN is ideally positioned for long-term, sustainable growth because to its strong financial results and proactive approach.

  • Concentrix (CNXC) Stock Soars Following Strong Earnings Report

    Concentrix (CNXC) Stock Soars Following Strong Earnings Report

    Following the announcement of its first-quarter 2025 financial results, shares of Concentrix Corporation (NASDAQ: CNXC) have seen a considerable boost in value. Investors reacted favorably to the fiscal year’s good start, which caused the price of CNXC shares to rise 36.65% to $62.42 as of the last check.

    Positive Financial Outcomes

    For the fiscal first quarter, ended February 28, 2025, Centrix recorded revenues of $2.37 billion, a 1.3% year-over-year reduction. Nevertheless, when currency fluctuations are taken into consideration, the company’s sales grew by 1.3% over the previous year.

    A stable operating environment contributed to the operating income’s 7.1% growth to $168.9 million for the quarter. Additionally, compared to the same time last year, diluted profits per share (EPS) increased from $0.76 to $1.04.

    Strategic Attention on Technology Integration and GenAI

    Concentrix emphasized its strategic focus on using cutting-edge technological solutions and Generative AI (GenAI) to boost customer success and encourage growth. To take advantage of new prospects, the organization keeps gaining exceptional business and improving its service skills.

    As a result, CNXC is still optimistic about its capacity to provide steady growth in currency sales, rising margins, and more free cash flow in 2025 and beyond.

    Share Repurchase Program

    Concentrix last month announced a $0.33275 quarterly dividend per share to be paid on May 6, 2025, to shareholders on the record on April 25, 2025. During the quarter, Concentrix paid $26.2 million to repurchase approximately 550,000 shares as part of its previously announced share repurchase program. As of February 28, 2025, CNXC had $582.3 million remaining in its buyback authorization.

    iX Hello 2.0’s Release Improves Customer Engagement

    Along with its impressive financial results, Concentrix unveiled iX Hello 2.0, a cutting-edge product that improves customer interaction with multi-modal bots, appointment scheduling, order status monitoring, and other features.

    Businesses may implement customized solutions across several channels, including webchat, voice, and applications, thanks to this platform’s great degree of customization. iX Hello 2.0 is a major step forward in CNXC’s efforts to streamline client interactions and enhance results across a range of sectors thanks to its simple setup and integration possibilities.

  • Pre-Market Momentum: Dermata Therapeutics (DRMA) Sees Sharp Gains

    Pre-Market Momentum: Dermata Therapeutics (DRMA) Sees Sharp Gains

    Dermata Therapeutics, Inc. (NASDAQ: DRMA) has seen a sharp gain in share price; the company is currently trading at $2.18, indicating a stunning 61.48% increase in pre-market activity. This spike comes after the company’s major Phase 3 clinical trial released encouraging early findings.

    Breakthrough Findings from the XYNGARI Trial

    The first Phase 3 study of Dermata Therapeutics’ once-weekly topical therapy XYNGARI, which treats moderate-to-severe acne, showed promising topline results. The findings indicated that XYNGARI had a good safety profile in addition to exhibiting excellent effectiveness. Patients responded favorably to the medication, with few adverse events and no significant side effects.

    After just 12 weeks of therapy, the Phase 3 Spongilla therapy for Acne Research (STAR-1) study demonstrated a statistically significant improvement when compared to a placebo, meeting all three of the main objectives. This result highlights XYNGARI’s potential as a successful acne therapy.

    Overcoming Obstacles in Patient Compliance

    The creation of XYNGARI represents a major breakthrough in acne therapy, especially considering that it is used once a week. The weekly schedule of XYNGARI may improve patient adherence in contrast to current FDA-approved topical acne therapies, which call for daily or twice-day administrations. By tackling patient compliance, a key obstacle to successful acne control, this invention may enhance overall treatment results.

    Strategies for Upcoming Research and Regulatory Submission

    Dermata Therapeutics is proceeding with planning for the Phase 3 STAR-2 study, which is scheduled to start in the second half of 2025, after receiving encouraging findings from the Phase 3 trial. A New Drug Application (NDA) filing to the U.S. Food and Drug Administration (FDA) is anticipated to be supported by further data from the STAR-2 trial and an open-label extension study.

    Additionally, DRMA is negotiating with possible partners for XYNGARI’s future cooperation and commercialization. Dermata Therapeutics (DRMA) is establishing XYNGARI as a potential addition to the acne treatment market with these ground-breaking findings, providing patients with a new, practical, and efficient choice.

  • Greenland Technologies (GTEC) Shares Rally In Pre-Hour Trading

    Greenland Technologies (GTEC) Shares Rally In Pre-Hour Trading

    After the release of financial results, Greenland Technologies Holding Corporation (NASDAQ: GTEC) shares saw a significant increase. As of the most recent pre-market check, GTEC stock price jumped 82.95% to $2.36.

    Adaptability in the Face of Market Difficulties

    Greenland Technologies (GTEC) demonstrated a strong focus on cost-efficiency by reporting a significant 28% reduction in operating expenditures, totaling $9.9 million. Furthermore, the company reversed its prior financial losses, turning a $15.15 million profit as opposed to a $25.02 million loss in 2023.

    Greenland Technologies has been resilient in the face of economic and business stresses, as well as difficulties among its clientele. The business’s steady sales growth and profitable recovery are positive indications of its long-term dominance in the sector.

    The favorable outcomes, which resulted in a net income of $1.03 per basic and diluted share, demonstrated GTEC’s emphasis on growing its commercial presence, especially in its product and vehicle lines.

    Product Offerings and Market Position Expansion

    Greenland Technologies has strategically expanded and diversified its product range, reinforcing its market position. In addition to its well-established transmission systems and integrated powertrains, the company now offers a range of all-electric, clean, and sustainable heavy equipment under its HEVI brand.

    These products aim to provide viable alternatives to traditional heavy-emission systems in the industrial sector. The successful launch of seven industrial heavy equipment models has garnered strong customer interest and support from ecosystem partners.

    Enhancing Technology and Production Effectiveness

    Greenland Technologies unveiled a new range of direct current (DC) mobile charging solutions as part of its continuous innovation efforts. These solutions are intended to fit in smoothly with fleets of electric vehicles at powered worksites. It is anticipated that this program will increase the use of HEVI’s electric heavy machinery while generating extra income.

    GTEC can reduce time-to-market and swiftly adjust to changing market needs thanks to its effective production process, which is backed by cutting-edge machinery, sophisticated systems, and trained personnel.

  • Soleno (SLNO) Stock Climbs In Pre-Hour Following Key FDA Decision

    Soleno (SLNO) Stock Climbs In Pre-Hour Following Key FDA Decision

    Following a major regulatory approval, Soleno Therapeutics, Inc. (NASDAQ: SLNO) stock has seen a sharp increase in value. SLNO shares were trading at $67.40 as of the recent pre-market check, representing a remarkable 37.64% rise. Following the U.S. Food and Drug Administration’s (FDA) approval of the company’s most recent medication for Prader-Willi syndrome (PWS), the stock has been rising.

    VYKAT XR is approved by the FDA

    Soleno Therapeutics’ VYKAT XR (diazoxide choline) extended-release tablets were officially approved by the FDA. Previously known as DCCR, this newly approved medication is designed to treat hyperphagia, an insatiable hunger disorder, in PWS children aged four and above. By April 2025, Soleno expects VYKAT XR to be commercially accessible in the US, providing a much-needed treatment alternative for individuals with the disease.

    A Revolution in the PWS Community

    For PWS patients and their families, the approval of VYKAT XR is a revolutionary development. The quality of life for both patients and caregivers has been greatly impacted by hyperphagia, which is thought to be the most incapacitating feature of the disease and has historically needed ongoing supervision and food restriction. The introduction of VYKAT XR provides new hope for managing this critical symptom, alleviating some of the burdens faced by families who have long struggled with the condition.

    Scientific Rigor and Safety Profile

    The FDA’s decision was supported by extensive clinical research and well-controlled studies demonstrating the efficacy and safety of VYKAT XR. Data from the clinical program indicated that patients who transitioned to a placebo experienced a statistically significant worsening of hyperphagia compared to those who continued with VYKAT XR. On average, participants had been on the medication for 3.3 years prior to the randomized withdrawal phase.

    VYKAT XR has demonstrated a well-established safety profile based on more than four years of safety data from several clinical investigations. Hypertrichosis, edema, hyperglycemia, and rash were the most often reported adverse effects, occurring in at least 10% of patients and at a rate 2% higher than placebo. These results support the medication’s ability to offer PWS patients significant comfort while keeping a tolerable safety level.